Eliquis vs Entresto
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Eliquis | US Entresto | |
|---|---|---|
| Generic name | apixaban | sacubitril/valsartan |
| Drug class | Factor Xa Inhibitor | ARNI (Neprilysin Inhibitor + ARB) |
| Treats | Blood clots, atrial fibrillation | Chronic heart failure |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Bristol-Myers Squibb/Pfizer | Novartis |
| Year approved | 2012 | 2015 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $350M | $150M |
| Common side effects | Serious bleeding risk, Bruising easily, Prolonged bleeding from cuts, Blood in urine or stool | Low blood pressure, High potassium, Kidney problems, Dizziness |
Frequently asked questions
Is Eliquis or Entresto better?
Neither is universally "better." Eliquis (apixaban) and Entresto (sacubitril/valsartan) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Eliquis and Entresto?
Eliquis is a Factor Xa Inhibitor made by Bristol-Myers Squibb/Pfizer, while Entresto is a ARNI (Neprilysin Inhibitor + ARB) made by Novartis. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Eliquis has the larger estimated TV advertising budget of the two.